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Bardet-Biedl syndrome (BBS) is a genetic disorder with the primary features of obesity, pigmentary retinopathy,
polydactyly, renal malformations, mental retardation, and hypogenitalism. Patients with BBS are also at increased
risk for diabetes mellitus, hypertension, and congenital heart disease. BBS is known to map to at least six loci:
11q13 (BBS1), 16q21 (BBS2), 3p13-p12 (BBS3), 15q22.3-q23 (BBS4), 2q31 (BBS5), and 20p12 (BBS6). Although
these loci were all mapped on the basis of an autosomal recessive mode of inheritance, it has recently been
suggested—on the basis of mutation analysis of the identified BBS2, BBS4, and BBS6 genes—that BBS displays a
complex mode of inheritance in which, in some families, three mutations at two loci are necessary to manifest the
disease phenotype. We recently identified BBS1, the gene most commonly involved in Bardet-Biedl syndrome. The
identification of this gene allows for further evaluation of complex inheritance. In the present study we evaluate
the involvement of the BBS1 gene in a cohort of 129 probands with BBS and report 10 novel BBS1 mutations.
We demonstrate that a common BBS1 missense mutation accounts for ∼80% of all BBS1 mutations and is found
on a similar genetic background across populations. We show that the BBS1 gene is highly conserved between mice
and humans. Finally, we demonstrate that BBS1 is inherited in an autosomal recessive manner and is rarely, if ever,
involved in complex inheritance.
Introduction
Bardet-Biedl syndrome (BBS [MIM 209900]) is a ge-
netically heterogeneous disorder mapping to six known
loci on chromosomes 11 (BBS1) (Leppert et al. 1994),
16 (BBS2) (Kwitek-Black et al. 1993), 3 (BBS3) (Shef-
field et al. 1994), 15 (BBS4) (Carmi et al. 1995), 2
(BBS5) (Young et al. 1999), and 20 (BBS6) (Katsanis et
al. 2000). The phenotype consists of central obesity, ret-
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inopathy, postaxial polydactyly, hypogonadism, renal
anomalies, and mental retardation or developmental de-
lay (Green et al. 1989; Beales et al. 1999). Other com-
ponents of the phenotype include diabetes mellitus, hy-
pertension, and congenital heart disease (Harnett et al.
1988; Elbedour et al. 1994). There has been substantial
interest in understanding the molecular basis and bio-
chemical pathways involved in Bardet-Biedl syndrome,
because some components of the phenotype are com-
mon. Four genes involved in BBS have now been iden-
tified. Two groups working independently identifiedmu-
tations in patients with BBS, in a gene previously shown
to cause McKusick-Kaufman syndrome (the MKKS
gene, now also known as “BBS6”) (Katsanis et al. 2000;
Slavotinek et al. 2000). We used positional cloning to
identify the genes causing BBS2 (Nishimura et al. 2001),
BBS4 (Mykytyn et al. 2001), and, most recently, BBS1
(Mykytyn et al. 2002). The MKKS protein product
shows similarity to type II chaperonins, and the BBS4
protein product shares homology with the O-linked ace-
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tylglucosamine transferase family of genes. The BBS1
and BBS2 protein products show no similarity to any
proteins with known function.
Katsanis et al. (2001) recently hypothesized that in
some cases the development of BBS requires the presence
of three disease-causing mutations (two mutations at
one locus and a third mutation at a second locus), a
form of complex inheritance termed “triallelic inheri-
tance.” The triallelic hypothesis is based on screening
of a cohort of 163 families with BBS for sequence var-
iations in both BBS2 and BBS6. This resulted in (1) the
identification of three apparent mutant alleles in four
pedigrees; (2) the detection of an unaffected individual
in each of two pedigrees who carry two BBS2 muta-
tions, but not a BBS6 mutation; and (3) the presence
of homozygosity of anonymous polymorphic markers
at one BBS locus, in combination with the presence of
a single mutant allele at a second locus in some small
families. In a subsequent article, Katsanis et al. (2002)
screened the same BBS cohort, along with some addi-
tional families, for mutations in the BBS4 gene. They
extended the triallelic hypothesis to include the possi-
bility of tetra-allelic inheritance, on the basis of the iden-
tification of a patient who is homozygous for bothBBS2
and BBS4 missense variants.
We recently used positional cloning to identify the
BBS1 gene (Mykytyn et al. 2002), which is the gene
thought, on the basis of linkage studies, to be most
commonly involved in BBS. BBS1mutations were found
in each of six extended pedigrees mapping to the BBS1
locus. Each of the six families had either a homozygous
mutation (three families) or compound heterozygous
mutations. In addition, a screen for BBS1 mutations in
60 unrelated probands confirmed that this gene is com-
monly involved in BBS, and the screen resulted in the
identification of a commonmissense mutation (M390R)
that is involved in approximately one-third of all BBS
cases in this patient cohort. In addition, we presented
preliminary data indicating that BBS1mutations do not
participate in triallelic inheritance. This conclusion was
based on the sequencing of the BBS2, BBS4, andMKKS
genes in six families with BBS1 and in 10 unrelated in-
dividuals who were homozygous for the BBS1 M390R
mutation, without finding any additional mutations.
The identification of four BBS genes, including the
gene most commonly involved in Bardet-Biedl syn-
drome, provides the opportunity to thoroughly ex-
amine whether BBS is inherited in a complex fashion.
In this article, we present results from the evaluation of
a large BBS cohort and report that we find no evidence
for complex inheritance involving the BBS1 locus. In
addition, we report the identification of 10 novel BBS1
mutations.
Patients and Methods
Patients and Families
Signed informed consent was obtained from each
patient and family member, using protocols approved
by the institutional review board at the University of
Iowa and collaborating institutions. The diagnosis of
BBS was based on clinical examination, using diagnostic
criteria that consist of the presence of at least three of
the cardinal features of BBS (obesity, polydactyly, renal
anomalies, retinopathy, hypogonadism, and mental re-
tardation). Retinopathy was diagnosed mainly by oph-
thalmoscopy. Electroretinography was also performed in
some patients. Nearly all patients were of northern Eu-
ropean ancestry.
Mutational and Genetic Analysis
Mutation detection was performed by direct sequenc-
ing of PCR amplification products. Primer sequences are
available upon request from the corresponding author.
In some cases, coding sequences of BBS1 were screened
by SSCP, followed by direct DNA sequencing. Ampli-
cons for SSCP analysis were designed to be ∼200 bp.
For SSCP, PCR products were separated on native gels
(7 ml of 50% glycerol, 3.5 ml 5# TBE, 8.8 ml 37.5:1
acrylamide:bis, and 50.7 ml ddH2O) for 3–4 h in 0.5#
TBE at room temperature, with the temperature con-
trolled by a cooling fan. The bands were visualized by
silver staining (Bassam et al. 1991). Abnormal variants
were sequenced and compared with a control sample
(CEPH sample 1331-01) to detect any changes from that
of the normal sequence.
PCR products for sequencing were amplified in a 25-
ml reaction volume and visualized on 1.2% agarose gels.
The corresponding bands were excised and purified us-
ing the QIAquick gel extraction kit (Qiagen). Plasmid
DNA (150 ng in 4.5 ml) or 4.5 ml of purified PCR product
was used as template for sequencing reactions. For plas-
mid, 5 pmol of primer and 2 ml of terminator sequencing
mix (Applied Biosystems) were added for a final reaction
volume of 10 ml. For PCR products, 10 pmol of primer
and 1 ml of terminator sequencing mix were added for
a final reaction volume of 10 ml. Cycling conditions were
as specified by the manufacturer. Plasmid sequencing re-
actions were precipitated in the presence of linear ac-
rylamide and were resuspended in 2 ml of loading buffer.
PCR product sequencing reactions were plate precipi-
tated in the presence of glycogen and isopropanol. The
reactions were analyzed on an ABI 3700 sequencer.
Genotyping
We performed PCR amplification for the analysis of
STRPs, using 40 ng of genomic DNA in 8.4-ml reaction
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Table 1
Mutations in Patients with BBS
Exon DNA Change Protein Change
1 c.(3)_37del M1?
4 c.339TrG Y113X
4 c.342delGa V114fsX150
8 c.599_604del I200_T201del
10 c.851delA Y284fsX288
11 c.1040delT M347fsX373
12 c.1130_1134delb C377_F378delfsX412
13 c.1318CrT R440X
15 c.1514_1515del L505fsX556
15 c.1553TrCc L518P
NOTE.—Unless indicated, all mutations were
found in combination with M390R.
a Detected in combination with the L518P
mutation.
b Detected in the homozygous state.
c Detected in 3 patients and in 0/96 control
subjects.
volumes containing 1.25 ml of 10# PCR buffer (100
mM Tris-HCl [pH 8.8]; 500 mM KCl; 15 mM MgCl2;
0.01% gelatin [w/v]; 200 mM each of dATP, dCTP,
dGTP, and dTTP; 2.5 pmol of each primer; and 0.2 U
of Taq polymerase [Bioline]). Samples were subjected to
35 cycles of 94C (50C, 52C, 55C, or 57C, as re-
quired) for 30 s and 72C for 30s. Amplification prod-
ucts were separated on 6% polyacrylamide gels con-
taining 7.7 M urea at 60 W for ∼2 h. Gels were silver
stained, as described above.
We obtained oligonucleotide primers for the STRPs
as MapPairs (Research Genetics). The custom primers
required for this study were designed using the Primer3
program and were synthesized commercially (Research
Genetics or Integrated DNA Technologies). For markers
that proved difficult to amplify using the standard Taq
polymerase, we substituted an equal amount of Ampli-
Taq (Applied Biosystems), along with an initial incu-
bation of the PCR mixture at 94C for 10 min.
Identification of BBS1 Homologues
To identify the mouse ortholog of BBS1, we used the
human BBS1 DNA sequence to search the mouse ge-
nome subdivision of the Celera sequence database. A
500-Mb contig containing the entire Bbs1 coding se-
quence was identified and downloaded. The coding ex-
ons were then assembled into a contig and were con-
ceptually translated. Similarity scores were calculated
using the BLOSUM62 amino acid similarity matrix. We
identified homologous bovine, zebrafish, and honeybee
sequences by searching the translated EST database con-
taining sequences from organisms other than human or
mouse. Sequences were aligned using the ClustalW and
Multiple Alignment programs (Baylor College of Med-
icine) and were formatted using the Boxshade program
(EMBnet).
Results
Mutation Analysis of BBS1
Linkage analysis studies have suggested that BBS1 is
the most common BBS locus, accounting for one-third
to one-half of all BBS cases (Bruford et al. 1997). We
reported elsewhere that screening of the BBS1 gene in
60 unrelated probands with BBS by SSCP analysis iden-
tified 22 individuals who had at least one copy of the
M390R mutation, with 16 of these individuals being
homozygous for this variant (Mykytyn et al. 2002). We
have now screened a total of 129 unrelated individuals
with BBS (including 69 previously unreported probands)
for the M390R mutation, using SSCP analysis and/or
direct sequencing. Of the 129 probands, 39 have at least
one copy of the M390R mutation, and 27 demonstrate
homozygosity for M390R, indicating that this mutation
is involved in 30% of all BBS cases in our cohort. We
sequenced the entire BBS1 gene in those individuals who
were heterozygous for the M390R mutation, and we
identified a second BBS1 mutation in 10 of 12 cases
(table 1). These mutations are nonsense and deletion
mutations, with the exception of one missense mutation
(L518P) that was not found in 192 northern European
control chromosomes. SSCP analysis of the entire BBS1
gene in 60 patients revealed 2 patients with 2 non-
M390R mutations (table 1). These data indicate that, in
at least 32% (41/129) of the probands in this cohort,
the BBS phenotype is caused by mutations in BBS1, and
the M390R mutation accounts for ∼80% of BBS1 dis-
ease-associated alleles in this population.
Evaluation of Complex Inheritance Involving BBS1
We reported elsewhere the sequencing all of the known
BBS genes (BBS2, BBS4, and MKKS) in probands from
our six families with BBS1 and in 10 unrelated probands
homozygous for the BBS1 M390R mutation, to search
for additional mutations (Mykytyn et al. 2002). We did
not identify any additional mutations in any of these
individuals. To further evaluate the involvement ofBBS1
in complex inheritance, we have now sequenced the
BBS2, BBS4, and MKKS genes in a total of 43 unrelated
probands, each having two BBS1 mutations. Although a
few sequence variants were detected (table 2), they are all
likely to be non–disease-causing polymorphisms, because
they result in a conservative amino acid substitution, do
not segregate in a manner consistent with disease cau-
sation, and/or are found in control individuals.
We previously identified three large Bedouin kin-
dreds with multiple affected individuals, each of
which mapped to a different BBS locus (BBS2, BBS3,
and BBS4) (Kwitek-Black et al. 1993; Sheffield et al.
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Table 2
Other Sequence
Variations in
Patients with BBS
Gene Variation
BBS2 I123V
BBS2 A504V
BBS4 K46R
BBS4 I70V
BBS4 T354I
MKKS A8T
MKKS R517C
MKKS G532V
1994; Carmi et al. 1995). Analysis of the inheritance
pattern in each of these large pedigrees indicates auto-
somal recessive inheritance. Mutation analysis of the
family with BBS2 indicates that all 11 affected individ-
uals are homozygous for the BBS2 mutation. In addi-
tion, none of the 26 unaffected first-degree relatives have
two copies of the mutation. All 14 affected members of
the kindred with BBS3 are homozygous for the chro-
mosome 3 disease haplotype, and none of the 36 un-
affected first-degree relatives are homozygous for the dis-
ease haplotype. The BBS3 gene has yet to be identified,
so we cannot confirm the haplotype data by mutation
analysis. All eight affected individuals of the Bedouin
family with BBS4 are homozygous for the disease-
associated haplotype, as well as for the disease mutation.
One of the 18 unaffected first-degree relatives in this
family (a parent of affected individuals) was homozy-
gous for the disease-associated haplotype. However, se-
quencing of the BBS4 gene reveals that this individual
is heterozygous for the disease-causing mutation. In the
three families combined, 80 unaffected first-degree
relatives of patients with BBS were analyzed for the
kindred-specific mutation or disease-associated hap-
lotype, without detecting any unaffected homozygous
individuals.
To determine whether BBS1 could contribute a third
mutant allele in the three large Bedouin families with
BBS, we sequenced the BBS1 gene in an affected proband
from each kindred. No BBS1 sequence variants were
identified. Finally, in six multiplex families in which af-
fected individuals had two BBS1 mutations, none of 28
unaffected first-degree relatives were homozygous or
compound heterozygous for BBS1mutations, indicating
complete disease penetrance.
Haplotype Analysis of the M390R Mutation
The identification of a single mutant BBS1 allele
(M390R) involved in 130% of all BBS cases and 80%
of all BBS1 disease-associated alleles, led us to ask
whether this mutation was a recurrent one or whether
these patients had inherited it from a common ancestor.
We developed STRPs from an ∼450-kb region surround-
ing the BBS1 gene. Each genetic marker was genotyped
in 14 unrelated control individuals of northernEuropean
descent to determine the approximate heterozygosity.
Seventeen unrelated patients with BBS (also northern
European) who were homozygous for the M390R mu-
tation were also genotyped with these genetic markers.
A marked reduction in the level of heterozygosity was
observed in the BBS groupwhen comparedwith the group
of randomly selected individuals (table 3). This result sug-
gests that the M390R mutation might be a relatively an-
cient mutation that arose on a single haplotype and is
identical by descent in our patient population.
When haplotypes were constructed for the 17 patients
with BBS1 who demonstrated homozygosity for the
M390R mutation and 7 patients heterozygous for the
M390R mutation, nearly all of the patients were ob-
served to have inherited a common haplotype (fig. 1A).
A few differences were detected within the conserved
haplotype that might have arisen because of a new mu-
tation at the STRP locus. Only 3 of the 41 M390R-
associated haplotypes that were examined differed at
more than one marker within the region surrounding
the BBS1 gene. This finding further indicates that the
M390R mutation is an ancient mutation and that pa-
tients with this mutation have inherited it from a com-
mon ancestor.
We then examined the haplotypes of the chromosomes
carrying a non-M390R mutation in the seven patients
with BBS who had inherited the M390R mutation in
the heterozygous state. The second mutation in these
patients included the following: Y113X, R440X, L518P
(two patients), E549X, c.599-604del, and one unknown.
The haplotypes of the chromosomes not carrying
M390R were found to exhibit extensive variation from
each other and from the M390R haplotype (fig. 1B).
We previously used five multiplex Puerto Rican fam-
ilies to aid in the positional cloning of the BBS1 gene.
In one family, the affected members were homozygous
for the M390R mutation; in one family, they were ho-
mozygous for the E549X mutation; in two families, they
were compound heterozygotes for the M390R mutation
and the E549X mutation; and, in one family, they were
compound heterozygotes for the E549X mutation and
a c.4321GrA splice site mutation (Mykytyn et al.
2002). The M390R mutation in these families is found
on the same genetic background as in the northern Eu-
ropean population. Interestingly, when haplotypes were
constructed, it was observed that all three Puerto Rican
mutations (M390R, E549X, and c.4321GrA) appear
to have occurred on a common genetic background (fig.
1C). Only the marker 001107-CTATT near the BBS1
gene was found to exhibit a difference among the three
mutations, and that difference was a single repeat unit
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Table 3
Heterozygosity of Markers Surrounding BBS1
MARKER
DISTANCE
(kb)
NO. OF
OBSERVED
ALLELES
FREQUENCY OF
M390R-ASSOCIATED
ALLELE HETEROZYGOSITY
Control Patient Control Patient
001107-AAT 4 .31 .84 .69 .29
001107-TAGA 87.9 4 .43 .96 .59 .06
001107-TGA 71.5 4 .58 1.00 .59 .00
001107-TTTA 2.5 2 .81 1.00 .31 .00
001107-ATTT 17.4 4 .32 .94 .65 .12
001107-CTATT 56.3 7 .19 .66 .74 .47
001107-CTTTT 32.5 4 .43 1.00 .56 .00
019220-TAAAA 52.0 4 .25 .97 .59 .06
019220-AG 14.9 5 .32 .91 .67 .18
019220-AAT 56.7 4 .54 .88 .60 .24
019220-TG 54.8 4 .75 1.00 .40 .00
Average .45 .92 .58 .13
NOTE.—BBS1 is located between 001107-CTTTT and 019220-TAAAA.
difference. The difference of a single repeat unit can be
explained by the occurrence of a new mutation event at
this locus on the common haplotype.
Since all three mutations in the Puerto Rican patients
with BBS appeared to have occurred on a similar hap-
lotype, we wished to determine whether or not this par-
ticular haplotype was prevalent in this population. A
total of 10 unrelated carriers were available for study
from the Puerto Rican families with BBS. The disease-
associated haplotype could be determined for all 10 sam-
ples. Only 1 of 10 non–disease-associated haplotypes
displayed similarity to the disease-associated haplotype
in this population (fig. 1D). Thus, it appears that the
disease-associated haplotype is not commonly found in
this population.
Evolutionary Conservation of BBS1
We were interested in determining the conservation
of BBS1 across species. We were able to determine the
mouse sequence for BBS1 by sequence alignment of the
human cDNA sequence against the Celera mouse ge-
nome database. This procedure identified a 500-Mb con-
tig containing the entire coding sequence of mouseBbs1.
We were then able to assemble the individual mouse
exons to generate the full-length coding sequence. Trans-
lating the mouse cDNA yields a sequence of 593 amino
acids, which is also the length of human BBS1. Com-
paring the human and mouse protein sequence reveals
that they are 92% identical and 96% similar (fig. 2A).
To ask how well conserved the methionine at position
390 is across more-diverse species, we performed a
BLAST search with the BBS1 amino acid sequence
against a translated EST database containing sequences
from organisms other than human or mouse. These anal-
yses demonstrate that the methionine at position 390 is
conserved across many species, including mouse, cow,
zebrafish, and honeybee (fig. 2B), providing additional
support that M390R is a disease-causing mutation.
BLAST analysis indicates the leucine at position 518 is
conserved in rat, although in mouse there is a noncon-
servative substitution of histidine (fig. 2A). The substi-
tution of a proline seen in three patients likely has a
deleterious effect on the structure of the protein.
Discussion
The recent identification of the BBS1 gene provides the
opportunity to further evaluate the hypothesis that BBS
displays complex inheritance. Examination of this hy-
pothesis could facilitate the understanding of complex
inheritance in other disorders, as well as aid in the un-
derstanding of the biochemical pathways involved in
BBS-associated phenotypes. In addition, determination
of the frequency of complex inheritance of BBS is req-
uisite in providing proper recurrence-risk estimates to
family members at risk of BBS . The complex inheritance
hypothesis predicts each of the following: (1) When
examining a gene commonly involved in BBS, one
should be able to identify a subset of affected indi-
viduals that have only a single mutant allele in that
gene. (2) In individuals with two mutations in one
gene, one should be able to identify an additional mu-
tation in one of the other BBS genes. (3) Some first-
degree relatives with two mutant alleles at one locus
should be clinically unaffected, because their genotype
at the second locus is normal.
With respect to each of the above criteria, we find no
evidence for complex inheritance in our study. First, we
have identified 41 families too small for individual link-
age analysis, in which the affected patients have at least
Figure 1 Haplotype analysis of the BBS1 locus. A, Summary of the haplotype analysis of 41 chromosomes carrying the M390Rmutation.
The number of times each haplotype was observed is shown below each haplotype. Differences from the conserved haplotype are indicated in
red. Of the 41 chromosomes, 19 correspond to a single haplotype, and 38/41 chromosomes differ at no more than one marker. B, Haplotype
analysis of seven chromosomes carrying a non-M390R mutation in individuals of northern European descent. Differences from the M390R-
associated haplotype are indicated in red. C, Haplotype analysis of the three disease-associated alleles identified in the Puerto Rican population.
Differences from the M390R-associated haplotype are indicated in red. D, Ten non–disease-associated haplotypes from Puerto Rican BBS1
heterozygous individuals. Differences from the M390R-associated haplotype are indicated in red. WT p wild type.
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Figure 2 Evolutionary conservation of BBS1. A, Alignment of human BBS1 amino acid sequence with mouse Bbs1. Identical amino acids
are shaded in black and conserved amino acids are shaded in gray. B, Alignment of human (Hsa) BBS1 peptide sequence and mouse (Mmu),
bovine (Bta), zebrafish (Dre), and honeybee (Ame) peptide sequences surrounding the methionine at position 390 (indicated by an arrow).
one BBS1 mutation. In all but two cases, sequencing of
the coding region and flanking splice sites identified the
second mutant allele. In the two instances in which we
identified only a single mutant BBS1 allele, the patients
did not have mutations in the BBS2, BBS4, or MKKS
genes. These data are consistent with our previous study
in which the sequencing of the BBS1 gene in 12 families
that contained two BBS2, BBS4, or MKKS mutations
failed to identifyBBS1mutations (Mykytyn et al. 2002).
These data lead to the conclusion that a mutation in
BBS1 does not contribute to complex inheritance in-
volving the other BBS loci.
Second, complete sequencing of the coding sequence
and flanking spice sites in the BBS2, BBS4, and MKKS
genes in 43 unrelated patients with BBS with two mu-
tant BBS1 alleles failed to identify additional mutant
alleles. These data indicate that homozygous or com-
pound heterozygous BBS1 mutations are sufficient for
disease penetrance.
Third, in the examination of 80 unaffected first-de-
gree relatives of patients with BBS in three large kin-
dreds, we found no evidence of two mutant alleles (i.e.,
no evidence of reduced penetrance). Furthermore, no
evidence of reduced penetrance was found in numerous
parents and unaffected siblings of patients from small
kindreds with BBS1. These combined data make it un-
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likely that complex inheritance is commonly involved
in BBS, and they indicate that, in the vast majority of
cases, BBS is inherited in an autosomal recessive pattern.
We conclude that families who have two mutations in
BBS1 should be assigned recurrence risks according to
a traditional autosomal recessiveMendelian inheritance
model.
Our data confirm that BBS1 is the most common BBS
locus and that a single mutation accounts for the ma-
jority of BBS1 cases. Our method of mutation screening
was to screen all patients first for the M390R mutation.
In those patients who had only one copy of the M390R
variant, the full coding region and consensus splice sites
were sequenced. Although this approach may not detect
all mutations, the distribution of M390R mutations
among homozygotes and heterozyotes indicates that we
are detecting most BBS1 mutations in our cohort by
this approach. This is evident by the fact that Hardy-
Weinberg equilibrium is present in those patients with
at least one copy of the M390R mutations ( 8pp 0.
based on observed homozygote frequency of 2p p
, with expected heterozygote frequency of0.64 2pqp
and observed heterozygote frequency of0.32 2pqp
, where p is the allele frequency of M390R and q0.29
is the allele frequency of all non-M390R mutations).
We also report haplotype analysis of the common
BBS1 M390R mutation. Our data suggest that the
M390R mutation is an ancient mutation, because it
resides on a single haplotype both within and across
populations. Interestingly, when we examine the mu-
tation-associated haplotypes of our Puerto Rican pa-
tients, we find that they all share a similar haplotype,
regardless of the mutation. It is unclear why multiple
mutations would arise on a similar haplotype. It is pos-
sible that the disease haplotype was common in the
Puerto Rican population when the mutations first arose
or that the disease-associated haplotype is more sus-
ceptible to mutation.
A wide range of inter- and intrafamilial clinical var-
iation in families with BBS has been documented (Riise
et al. 1997, 2002). It is likely, on the basis of these
clinical observations, that there are other genes that
modify the effects of mutations in BBS genes. These
modifier genes may be the BBS genes themselves or other
genes that code for proteins that interact with the BBS
proteins directly or indirectly. The present study, in
which we did not find evidence to support complex
inheritance, does not exclude the possibility that se-
quence alterations or expression differences at one BBS
locus might influence the phenotype caused by recessive
mutations at another BBS locus. The study of such gene
interactions will be greatly facilitated by the develop-
ment of BBS animal models. The recent identification
of four BBS genes will enable the development of these
models.
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